Clinical Trials Logo

Lichen Planus, Oral clinical trials

View clinical trials related to Lichen Planus, Oral.

Filter by:

NCT ID: NCT06158113 Recruiting - Oral Lichen Planus Clinical Trials

Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study

Start date: March 13, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn the effects of baricitinib (the study drug) in patients with Oral Lichen Planus. The main questions it aims to answer are: - What is the efficacy of baricitinib in treating moderate to severe Oral Lichen Planus? - Can baricitinib treatment in Oral Lichen Planus change quality of life? - What side effects do patients with Oral Lichen Planus experience when treated with baricitinib? Participants will be required to come in to monthly visits for up to eight months. During visits, participants will be: - Evaluated for the extent of their disease - Asked to fill out a questionnaire about their quality of life - Given baricitinib for them to take at home for six months - Evaluated for any potential side experienced while on treatment - Asked to return 1 month after completing treatment

NCT ID: NCT06135805 Recruiting - Oral Lichen Planus Clinical Trials

Impact of Fluocinonide 0,05% in Oral Lichen Planus

Start date: October 27, 2020
Phase: N/A
Study type: Interventional

A double-blind placebo-controlled trial is conducted in order to evaluate the efficacy of Fluocinonide 0,05% and determinate the statistical significance of the outcome variables. Oral cavity lichen is a chronic inflammatory condition affecting the mucosa of the oral cavity , which significantly reduces the quality of life of affected individuals.

NCT ID: NCT06135259 Not yet recruiting - Oral Lichen Planus Clinical Trials

Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus

Start date: May 20, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the clinical efficacy of erythropoietin gel containing a solution of 4000 units with triamcinolone acetonide 0.1% gel in the treatment of symptomatic oral lichen planus (OLP)

NCT ID: NCT06119672 Recruiting - Oral Lichen Planus Clinical Trials

Efficacy of Probiotic Capsules With Topical Clobetasol Propionate in OLP Treatment

Start date: May 1, 2023
Phase: Phase 3
Study type: Interventional

Oral lichen planus patients who will meet inclusion criteria will be divided into 2 groups -The intervention group (Group P): This group will be randomly allocated to take one capsule twice daily during meal time at morning and evening of probiotics complex obtained from Biovea for 4 -week study period. Moreover, patients in this group will be instructed to apply clobetasole propionate in orabase gel 2 times daily for 4 weeks. Patients will receive their supply of the gel and probiotics every 2 weeks. The control group (Group B): This group will be randomly allocated to apply clobetasol propionate in orabase gel 4 times daily after meal times and before sleeping for 4 weeks. At the 3rd week this group will be instructed to apply miconazole gel 4 times daily as a prophylaxis for two weeks. Salivary sample collection: Unstimulated salivary sample was collected from all participants twice , once at baseline and another time after 4 weeks from the study period. Saliva was collected in graduated clear test tubes to be used in the evaluation of candidal counts before and after treatment . Patient's visits was at baseline, 2 weeks and 4 weeks.

NCT ID: NCT06078579 Recruiting - Oral Lichen Planus Clinical Trials

Salivary and Serum Leptin Levels in Oral Lichen Planus Patients: A Case-control Study.

Start date: December 30, 2023
Phase:
Study type: Observational

This study aims to evaluate the levels of leptin in both saliva and serum samples of patients diagnosed with oral lichen.

NCT ID: NCT06060301 Active, not recruiting - Oral Lichen Planus Clinical Trials

Topical Sulfasalazine and Oral Lichen Planus

Start date: March 1, 2023
Phase: Phase 3
Study type: Interventional

Oral lichen planus (OLP) is a chronic inflammatory disease that affects the mucosal membrane. T-cell mediated damage against the mucosal epithelial cells is implicated in the pathogenesis of OLP, although the exact mechanism is unknown. Sulfasalazine is extensively used in inflammatory bowel disease and is effective on immune-related inflammatory disease such as Crohn's disease, rheumatoid arthritis, and Behcet's disease. In spite of its effectiveness, the anti-inflammatory mechanism is not clearly understood.

NCT ID: NCT06042010 Completed - Oral Lichen Planus Clinical Trials

Oral Zinc Supplement as Adjunctive Therapy for Erosive Oral Lichen Planus

Start date: January 5, 2023
Phase: N/A
Study type: Interventional

Lichen Planus (LP) is a chronic mucocutaneous inflammatory disease and considered as T-cell mediated autoimmune disorder. Zinc is a potent antioxidant micronutrient that contributes to the proper functioning of the antioxidant defense system. In addition, this mineral protects cells against inflammation by oxidative stress, because it acts in the stabilization of cell membrane. It also maintains macrophage and neutrophil functions, natural killer cell activity, and complement activity. Matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases and have the main function of proteolytic degradation of connective tissue matrix proteins. Zinc prevents (MMP-1) activation and inhibition of the T-cell accumulation in (OLP) through inhibiting of (MMP-9). Aim of the study: To evaluate and compare the efficacy of adding oral zinc supplementation 50 mg to 0.1%Triamcinolone orabase (TA)versus 0.1%Triamcinolone orabase alone on the healing of erosive OLP.

NCT ID: NCT06033105 Completed - Clinical trials for Vitamin D Deficiency

Vitamin D Deficiency as a Risk Factor for the Development and Malignant Transformation of Oral Lichen Planus

Start date: August 1, 2023
Phase:
Study type: Observational

To investigate the role of Vitamin D (VD) deficiency as a risk factor for the development and malignant transformation of Oral lichen planus (OLP) taking into consideration sex, dietary habits, sun exposure, socioeconomic status and psychological factors.

NCT ID: NCT05997173 Recruiting - Oral Lichen Planus Clinical Trials

The Regulatory Role of Immune Response in Oral Lichen Planus

Start date: September 7, 2020
Phase:
Study type: Observational

Oral lichen planus (OLP) is a common chronic inflammatory disease of Oral mucosa. The pathogenesis of OLP is not clear, and there is no effective method to cure it. In vitro, previous studies have shown that oral mucosal mesenchymal stem cell cells (MSCs) can secrete Ido, which is involved in the pathogenesis of OLP. It has been proved that mental disorders such as depression and anxiety play an important role in the pathogenesis and treatment of OLP. Mental stress factors can cause abnormal changes of inflammatory factors, leading to immune dysfunction, which is also one of the main causes of OLP. In this study, we integrated the advantages of stomatology, psychiatry, neurobiology and traditional Chinese medicine, focused on the clinical problems of mental disorders with oral mucosal comorbidity, and assessed the depressive and anxiety status of OLP patients, so as to improve the therapeutic effect of OLP.

NCT ID: NCT05973097 Recruiting - Oral Lichen Planus Clinical Trials

Treatment of Oral Lichen Planus With Paeoniflorin and Photodynamic Therapy

Start date: July 30, 2023
Phase: N/A
Study type: Interventional

Oral lichen planus (OLP) is a common chronic inflammatory disease of the oral mucosa and is considered a precancerous condition. It is characterized by white reticular changes in the oral mucosa, which can progress to erosions and cause pain in severe cases. The pathogenesis of OLP is still unclear, but it is believed to be a T-lymphocyte-mediated autoimmune disease. Currently, only symptomatic treatments are available, and there is no definitive cure. In this project, we plan to use TCM differentiation to categorize OLP patients and conduct a randomized controlled clinical trial to demonstrate the enhanced therapeutic effect of paeoniflorin combined with photodynamic therapy for OLP. The implementation of this project will provide new insights into the clinical management of OLP, improve our understanding of the treatment mechanisms, and have important theoretical and clinical implications.